Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Lymphoma 7Leukemia 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Renal Cell 5Unspecified Adult Solid Tumor, Protocol Specific 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Myeloid, Acute 4Burkitt Lymphoma 4Kidney Neoplasms 3Waldenstrom Macroglobulinemia 2Stomach Neoplasms 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Multiple Myeloma 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Congenital Abnormalities 2Carcinoma, Ovarian Epithelial 2Blast Crisis 2Anemia, Refractory 2

Interventions

Cisplatin 182Radiotherapy 81Paclitaxel 80Brachytherapy 74Carboplatin 72pembrolizumab 63Bevacizumab 41Surveys and Questionnaires 29Colposcopy 29Radiation 28Gemcitabine 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 27Topotecan 26Magnetic Resonance Spectroscopy 24Blood Specimen Collection 23human papillomavirus vaccine, L1 type 16, 18 22Nivolumab 22Drug Therapy 22Papillomavirus Vaccines 20atezolizumab 19Platinum 19Radiotherapy, Intensity-Modulated 18Biopsy 18Docetaxel 17Taxes 16Cyclophosphamide 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × bryostatin 1 × Clear all
NCT00005965 2013-07-10

Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix

National Cancer Institute (NCI)

Phase 2 Completed
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡